
Originally Posted by
Wolfwood
210 participants with mild to moderate AD received either 200 mcg of huperzine A, 400 mcg of huperzine A, or placebo twice daily for 16 weeks. While no statistical difference in cognitive scores was noted in patients in the lower dose huperzine A (200mcg) group compared to placebo, the higher dose (400 mcg) of huperzine A led to improved cognition and activities of daily living.
Possibly the dosage then?
Bookmarks